337 related articles for article (PubMed ID: 31323990)
1. Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.
Pasini L; Ulivi P
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31323990
[TBL] [Abstract][Full Text] [Related]
2. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
4. Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.
Hur JY; Kim HJ; Lee JS; Choi CM; Lee JC; Jung MK; Pack CG; Lee KY
Mol Cancer; 2018 Jan; 17(1):15. PubMed ID: 29374476
[TBL] [Abstract][Full Text] [Related]
5. The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.
Bożyk A; Nicoś M
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295075
[TBL] [Abstract][Full Text] [Related]
6. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
7. Update on liquid biopsy in clinical management of non-small cell lung cancer.
Wu Z; Yang Z; Dai Y; Zhu Q; Chen LA
Onco Targets Ther; 2019; 12():5097-5109. PubMed ID: 31303765
[TBL] [Abstract][Full Text] [Related]
8. Understanding the Mechanisms of Resistance in
Del Re M; Crucitta S; Gianfilippo G; Passaro A; Petrini I; Restante G; Michelucci A; Fogli S; de Marinis F; Porta C; Chella A; Danesi R
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31416192
[TBL] [Abstract][Full Text] [Related]
9. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
10. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy using extracellular vesicle-derived DNA in lung adenocarcinoma.
Kim IA; Hur JY; Kim HJ; Lee SE; Kim WS; Lee KY
J Pathol Transl Med; 2020 Nov; 54(6):453-461. PubMed ID: 33027851
[TBL] [Abstract][Full Text] [Related]
12. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Rolfo C; Mack PC; Scagliotti GV; Baas P; Barlesi F; Bivona TG; Herbst RS; Mok TS; Peled N; Pirker R; Raez LE; Reck M; Riess JW; Sequist LV; Shepherd FA; Sholl LM; Tan DSW; Wakelee HA; Wistuba II; Wynes MW; Carbone DP; Hirsch FR; Gandara DR
J Thorac Oncol; 2018 Sep; 13(9):1248-1268. PubMed ID: 29885479
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
15. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients.
Malapelle U; Pisapia P; Rocco D; Smeraglio R; di Spirito M; Bellevicine C; Troncone G
Transl Lung Cancer Res; 2016 Oct; 5(5):505-510. PubMed ID: 27826531
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.
Pérez-Callejo D; Romero A; Provencio M; Torrente M
Transl Lung Cancer Res; 2016 Oct; 5(5):455-465. PubMed ID: 27826527
[TBL] [Abstract][Full Text] [Related]
17. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure.
Zhou J; Zhao C; Zhao J; Wang Q; Chu X; Li J; Zhou F; Ren S; Li X; Su C; Zhou C
Thorac Cancer; 2019 Apr; 10(4):957-965. PubMed ID: 30887673
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
19. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy in Tumor Genetic Diagnosis.
Jung A; Kirchner T
Dtsch Arztebl Int; 2018 Mar; 115(10):169-174. PubMed ID: 29587961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
